Oncology Decoded

Manojkumar Bupathi, MD, MS; and Benjamin Garmezy, MD, dove into the complexities of adjuvant therapy for kidney cancer, providing valuable insights for oncology clinicians in the latest episode of Oncology Decoded . The discussion began with a fundamental overview of adjuvant therapy, which aims to eradicate residual microscopic disease and mitigate the risk of cancer recurrence.    Bupathi, execu...

In the most recent episode of Oncology Decoded , co-hosts Manojkumar Bupathi, MD, MS, executive co-chair of Genitourinary Cancer Research Executive Committee at Sarah Cannon Research Institute and medical oncologist with Rocky Mountain Cancer Centers specializing in solid tumors and genitourinary cancers; and Benjamin Garmezy, MD, associate director of Genitourinary Research and executive co-chair...

This episode of Oncology Decoded tackled the challenging landscape of non-clear cell renal cell carcinoma (nccRCC), a heterogeneous group of tumors representing about 20% to 25% of all kidney cancers. The episode provided expert insights into the diagnosis and management of this complex disease.  Meet the panel discussants:  Manojkumar Bupathi, MD, MS, executive co-chair of Genitourinary Cancer Re...

When treating hormone-sensitive prostate cancer (mHSPC), one question can be, when is the right time to optimize or intensify therapy? In the latest Oncology Decoded podcast, genitourinary oncologists discuss the use of radiotherapy and define oligometastatic disease including preferred treatment options. The discussion took place during the 2025 ASCO Genitourinary Cancers Symposium.  The expert p...

During the 2025 ASCO Genitourinary Cancers Symposium, Oncology Decoded held their inaugural podcast with a live filming taking place at the conference. The first episode focused on bladder cancer specifically, neoadjuvant vs adjuvant therapy options and the use of cisplatin vs carboplatin.  Meet the expert panel involved in the discussion:     Manojkumar Bupathi, MD, MS, executive co-chair of Geni...